Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Inhibikase Therapeutics, Inc. IKT
$0.61
-$0.01 (-1.50%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
17395013.00000000
-
week52high
1.21
-
week52low
0.44
-
Revenue
123440
-
P/E TTM
-1
-
Beta
0.94209300
-
EPS
-0.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JonesTrading | Buy | 15 июл 2021 г. | |
| JonesTrading | Hold | Buy | 16 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Dion Gisele | A | 60000 | 60000 | 01 сент 2022 г. |
| Werner Milton H. | A | 5335433 | 5000 | 16 авг 2022 г. |
| BERMAN DENNIS N | A | 40000 | 40000 | 24 июн 2022 г. |
| O'Farrell Elizabeth G. | A | 40000 | 40000 | 24 июн 2022 г. |
| GRINT PAUL C | A | 40000 | 40000 | 24 июн 2022 г. |
| Freeman Roy Lester | A | 40000 | 40000 | 24 июн 2022 г. |
| Werner Milton H. | A | 5330433 | 5000 | 27 мая 2022 г. |
| Werner Milton H. | A | 5325433 | 10000 | 20 мая 2022 г. |
| FRATTAROLI JOSEPH | A | 48091 | 3948 | 19 мая 2022 г. |
| Werner Milton H. | A | 125000 | 125000 | 07 мар 2022 г. |
Новостная лента
Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?
InvestorPlace
26 янв 2023 г. в 09:56
Inhibikase Therapeutics (NASDAQ: IKT ) stock is falling on Thursday after the company announced a registered direct offering and private placement. Starting with the registered direct offering up 6,744,187 shares of IKT stock for a price of 86 cents each.
Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript
Seeking Alpha
15 ноя 2022 г. в 09:55
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2022 Earnings Conference Call November 15, 2022 8:00 AM ET Company Participants Alex Lobo – Stern Investor Relations Milton Werner – President and Chief Executive Officer Conference Call Participants Operator Good day, and welcome to Inhibikase Therapeutics' Third Quarter 2022 Financial Results Conference Call. All participants are in listen-only mode.
Inhibikase Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022
PRNewsWire
08 ноя 2022 г. в 08:00
BOSTON and ATLANTA , Nov. 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.
Inhibikase Therapeutics to Present at the Grand Challenges in Parkinson's Disease Conference
PRNewsWire
21 сент 2022 г. в 16:05
BOSTON and ATLANTA , Sept. 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D.
Inhibikase Therapeutics to Present Data from Phase 1/1b study of IkT-148009 at the Movement Disorders Society Congress
PRNewsWire
15 сент 2022 г. в 08:00
IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients No clinically significant adverse events observed Actively enrolling Phase 2a '201' clinical trial of IkT-148009 in patients with untreated Parkinson's disease BOSTON and ATLANTA , Sept. 15, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will present safety, tolerability, pharmacokinetics and exploratory Parkinson's assessment data from the Company's Phase 1/1b '101' study of IkT-148009 in Parkinson's disease at the International Congress of Parkinson's Disease and Movement Disorders tomorrow, September 16 th, 2022.